Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

BACKGROUND: Fluoropyrimidine drugs are extensively used for the treatment of solid cancers. However, adverse drug reactions are a major clinical problem, often necessitating treatment discontinuation. The aim of this study was to identify pharmacogenetic markers predicting fluoropyrimidine toxicity....

Descripción completa

Detalles Bibliográficos
Autores principales: Loganayagam, A, Arenas Hernandez, M, Corrigan, A, Fairbanks, L, Lewis, C M, Harper, P, Maisey, N, Ross, P, Sanderson, J D, Marinaki, A M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694243/
https://www.ncbi.nlm.nih.gov/pubmed/23736036
http://dx.doi.org/10.1038/bjc.2013.262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694243/
https://www.ncbi.nlm.nih.gov/pubmed/23736036
http://dx.doi.org/10.1038/bjc.2013.262

Ejemplares similares